famitinib
Small moleculeexperimental
Clinical trial activity
61 trials · 14 clinical orgs · 0 marketing orgs
Phase 1
17
Phase 2
50
Phase 3
10
Phase 4
0
Earliest trial started Jun 1, 2009 (NCT01762280)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Transitional Cell · Phase 2
- Cholangiocarcinoma · Phase 2
- Colorectal Neoplasms · Phase 3
- Endometrial Neoplasms · Phase 2
- Esophageal Squamous Cell Carcinoma · Phase 2
- Gastrointestinal Stromal Tumors · Phase 3
- Healthy Volunteers · Phase 1
- Lung Neoplasms · Phase 2
- Lymphoma · Phase 1/Phase 2
- Melanoma · Phase 2
- Nasopharyngeal Carcinoma · Phase 2
- Neoadjuvant Therapy · Phase 3
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Pharmacokinetics · Phase 1/Phase 2
- Sezary Syndrome · Phase 2
- Small Cell Lung Carcinoma · Phase 3
- Thyroid Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 3
- Uterine Cervical Neoplasms · Phase 3
Mechanism of action
Platelet-derived growth factor receptor inhibitor
Multi-targeted receptor tyrosine kinase inhibitor
FLT3 inhibitor
Multi-targeted receptor tyrosine kinase inhibitor
- Stem cell growth factor receptorINHIBITOR
KIT inhibitor
Multi-targeted receptor tyrosine kinase inhibitor
FLT1 inhibitor
Multi-targeted receptor tyrosine kinase inhibitor
KDR inhibitor
Multi-targeted receptor tyrosine kinase inhibitor
FLT4 inhibitor
Multi-targeted receptor tyrosine kinase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O- Mol. weight
- 410.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545026 ↗
- ChEMBLCHEMBL1278146 ↗
Also known as
- 5-(2-(diethylamino)ethyl0-2-9(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl)-3-methyl-6,7-dihydro-1h-pyrrolo(3,2-c)pyridin-4(5h)-one
- famitinib
- famitinib
- famitinib
- famitinib
- famitinib
- famitinib malate
- shr1020
- shr-1020
- shr-1020
- shr10201
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07143292 | Phase 2 | Nov 30, 2025 | Sun Yat-Sen University |
| NCT07147088 | Phase 2 | Sep 1, 2025 | Fudan University |
| NCT06913777 | Phase 3 | Apr 8, 2025 | Fudan University |
| NCT06516289 | Phase 2 | Jul 31, 2024 | Fudan University |
| NCT07309185 | Phase 2 | Jul 24, 2024 | Shandong Tumor Hospital |
| NCT06332950 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2024 | Jiao Tong University |
| NCT06336954 | Phase 2 | Mar 30, 2024 | Jiao Tong University |
| NCT06306560 | Phase 2 | Mar 15, 2024 | Harbin Medical University |
| NCT06332300 | Phase 2 | Feb 1, 2024 | Nanjing University |
| NCT06146985 | Phase 2 | Dec 1, 2023 | Jiao Tong University |
| NCT05999149 | Phase 3 | Sep 1, 2023 | Fudan University |
| NCT05760378 | Phase 3 | Mar 17, 2023 | Fudan University |
| NCT05670925 | Phase 2 | Mar 1, 2023 | Fudan University |
| NCT05594095 | Phase 2 | Dec 1, 2022 | Fudan University |
| NCT05473468 | Phase 1 | Aug 26, 2022 | Hengrui Therapeutics, Inc. |
| NCT05214976 | Phase 2 | Aug 12, 2022 | Hengrui Therapeutics, Inc. |
| NCT05336279 | Phase 1 | May 18, 2022 | Hengrui Therapeutics, Inc. |
| NCT05208177 | Phase 2 | Apr 22, 2022 | Hengrui Therapeutics, Inc. |
| NCT05147727 | Phase 1 | Jan 31, 2022 | Hengrui Therapeutics, Inc. |
| NCT05106335 | Phase 3 | Dec 31, 2021 | Hengrui Therapeutics, Inc. |
Showing 20 of 61 trials
Page 1 / 4
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 39 | 35 | 3 | 2009 |
| Fudan University | Academic/Hospital | 12 | 11 | 2 | 2012 |
| Sun Yat-Sen University | Academic/Hospital | 6 | 1 | 3 | 2011 |
| Huazhong University of Science and Technology | Academic/Hospital | 5 | 1 | 3 | 2014 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 4 | 1 | 2 | 2009 |
| Jiao Tong University | Academic/Hospital | 4 | 4 | 1 | 2021 |
| Peking University | Academic/Hospital | 3 | 1 | 2 | 2012 |
| Tianjin Medical University | Academic/Hospital | 3 | 3 | 1 | 2021 |
| Central South University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Harbin Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Henan Medical University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Nanjing University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2020 |
| Shandong Tumor Hospital | Academic/Hospital | 1 | 1 | 1 | 2024 |
14 organizations
Page 1 / 1